Crinetics Pharmaceuticals, Inc. (CRNX)

47,20 +0,42 (+0,90%) Al cierre: 04:00PM EDT

Crinetics Pharmaceuticals, Inc.

6055 Lusk Boulevard
San Diego, CA 92121
United States
858 450 6464
https://www.crinetics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 290

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. R. Scott Struthers Ph.D.	Founder, President, CEO & Director	978,34k	5,65M	1963
Dr. Stephen F. Betz Ph.D.	Founder & Chief Scientific Officer	672,66k	N/A	1966
Mr. Marc J. C. Wilson	Chief Financial Officer	642,25k	408,5k	1979
Mr. Jeff E. Knight	Chief Operating Officer	657,31k	N/A	1971
Dr. Alan S. Krasner M.D.	Chief Endocrinologist	653,92k	125,93k	1963
Mr. James Hassard	Chief Commercial Officer	623,5k	N/A	1966
Ms. Garlan Adams	General Counsel & Corporate Secretary	N/A	N/A	N/A
Ms. Adriana Cabre M.B.A.	Chief Human Resources Officer	N/A	N/A	N/A
Mr. Kevin Capps	Head of Intellectual Property	N/A	N/A	N/A
Mr. Chris Robillard M.B.A.	Chief Business Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de Crinetics Pharmaceuticals, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 4; Tablero: 7; Derechos de los accionistas: 8; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.